What is Experimur?
Experimur operates as a premier toxicology testing and research laboratory, providing essential services for the conduct of pre-clinical and regulatory toxicology studies. The firm maintains a comprehensive portfolio of capabilities, ranging from acute and chronic toxicity assessments to specialized investigations in teratology, reproduction, pharmacokinetics, and neurotoxicity. By adhering strictly to FDA, EPA, and OECD testing guidelines, as well as Good Laboratory Practices (GLP), Experimur serves as a vital link in the drug development and chemical safety pipeline. Its market position is defined by its technical rigor and its ability to provide high-fidelity data required for international regulatory submissions.
How much funding has Experimur raised?
Experimur has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$737K
Debt (2020): $350K with participation from PPP
Debt (2021): $737K led by PPP
Key Investors in Experimur
PPP
Public-Private Partnership
What's next for Experimur?
With the recent influx of capital, Experimur is well-positioned to expand its enterprise-level research capabilities. The strategic focus will likely shift toward enhancing laboratory automation and increasing throughput for complex pharmacokinetics and neurotoxicity studies. As the demand for stringent regulatory compliance grows globally, the firm is poised to capture additional market share by scaling its specialized testing services. Future initiatives will likely prioritize the integration of cutting-edge analytical technologies to maintain its competitive edge in the pre-clinical research market, ensuring that it continues to meet the evolving needs of its diverse client base in the pharmaceutical and biotechnology industries.
See full Experimur company page
